Vera Therapeutics CEO Sells Over $1 Million in Stock

Marshall Fordyce sold nearly 23,000 shares under a pre-arranged trading plan

Apr. 15, 2026 at 9:33pm

Got story updates? Submit your updates here. ›

An extreme close-up of various metal medical instruments and laboratory equipment, conveying the complex, high-tech nature of the biotech industry without using any text or identifiable branding.The sale of over $1 million in Vera Therapeutics stock by the CEO reflects routine portfolio management, not necessarily broader concerns about the company's future.Cambridge Today

Vera Therapeutics, Inc. (NASDAQ:VERA) CEO Marshall Fordyce sold 22,951 shares of the company's stock on Tuesday, April 14th for a total value of $1,010,991.55. The transaction represented an 8.89% decrease in Fordyce's ownership stake in the company, which he now owns 235,244 shares valued at $10,362,498.20.

Why it matters

Insider sales can provide insight into management's views on a company's prospects, though pre-arranged trading plans like the one used by Fordyce can limit the conclusions that can be drawn. Vera Therapeutics is a clinical-stage biotech focused on developing novel immunotherapies, an area that has seen significant investor interest and stock price volatility.

The details

Fordyce's stock sale was executed under a pre-arranged Rule 10b5-1 trading plan, which allows company insiders to schedule stock transactions in advance and avoid allegations of insider trading. The shares were sold at an average price of $44.05. Vera Therapeutics' stock has traded between $18.76 and $56.05 over the past 52 weeks and currently has a market capitalization of $3.1 billion.

  • The stock sale occurred on Tuesday, April 14th, 2026.

The players

Marshall Fordyce

The CEO of Vera Therapeutics, Inc.

Vera Therapeutics, Inc.

A clinical-stage biotechnology company focused on developing novel immunotherapies.

Got photos? Submit your photos here. ›

What they’re saying

“The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.”

— Vera Therapeutics, Inc.

What’s next

Investors will likely continue to monitor Vera Therapeutics' stock performance and any future insider transactions as the company advances its pipeline of immunotherapy candidates.

The takeaway

Insider sales, even when executed through pre-arranged trading plans, can still provide some insight into management's views on a company's prospects, though the conclusions that can be drawn are limited. Vera Therapeutics remains an interesting biotech play, but its stock price will likely continue to be volatile as the company progresses its clinical programs.